Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Boehringer Ingelheim
Colorcon
Medtronic
Harvard Business School

Last Updated: January 19, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLURAZEPAM HYDROCHLORIDE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for flurazepam hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00283790 Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo Completed Sanofi Phase 4 2006-01-01 Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator
NCT02350309 Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder Completed Eisai Inc. Phase 1 2015-01-01 This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage strengths of E2006 (5 mg and 10 mg) in subjects with insomnia disorder.
NCT02374567 Pharmacovigilance in Gerontopsychiatric Patients Recruiting Hannover Medical School Phase 3 2015-01-01 The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment. The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises. To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites. At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed. Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system. In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually. 2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for flurazepam hydrochloride

Condition Name

Condition Name for flurazepam hydrochloride
Intervention Trials
Depression 1
Sleep Deprivation 1
Dementia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for flurazepam hydrochloride
Intervention Trials
Disease 2
Psychophysiologic Disorders 1
Dementia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for flurazepam hydrochloride

Trials by Country

Trials by Country for flurazepam hydrochloride
Location Trials
United States 3
Lebanon 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for flurazepam hydrochloride
Location Trials
Kentucky 1
Georgia 1
New Jersey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for flurazepam hydrochloride

Clinical Trial Phase

Clinical Trial Phase for flurazepam hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for flurazepam hydrochloride
Clinical Trial Phase Trials
Completed 2
Not yet recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for flurazepam hydrochloride

Sponsor Name

Sponsor Name for flurazepam hydrochloride
Sponsor Trials
Saint-Joseph University 1
Hannover Medical School 1
Eisai Inc. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for flurazepam hydrochloride
Sponsor Trials
Other 2
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Express Scripts
AstraZeneca
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.